New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL) vs Vanda Pharmaceuticals Inc. (VNDA)

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and Vanda Pharmaceuticals Inc. are both Biotechnology companies. Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and Vanda Pharmaceuticals Inc. are of similar size ($237.8M and $235.2M). Across the 1 metrics below, Clinuvel Pharmaceuticals Ltd. - Sponsored ADR leads on 1 and Vanda Pharmaceuticals Inc. on 0.

Valuation

Metric CUVL VNDA Biotechnology median
P/E — n/m 8.49
P/S — 0.91 8.56
P/B — 1.04 2.04
Price to free cash flow — n/m 23.84
EV/EBITDA — n/m 0.69
EV/Sales — 0.30 8.00
Earnings yield — (134.30%) (35.81%)
Free cash flow yield — (72.10%) (25.41%)

Profitability

Metric CUVL VNDA Biotechnology median
Gross margin — 93.59% 70.18%
Operating margin — (77.59%) 0.00%
Net margin — (119.87%) 0.00%
Free cash flow margin — — 0.00%
Return on equity — (82.55%) (51.58%)
Return on assets — (55.89%) (45.91%)
Return on invested capital — (180.19%) 0.00%

Growth

Metric CUVL VNDA Biotechnology median
Revenue growth (TTM) — 8.11% 7.20%
EPS growth (last fiscal year) (2.13%) (1,033.33%) 29.04%
Revenue growth, 5-year CAGR — (2.73%) 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric CUVL VNDA Biotechnology median
Debt to equity — 0.01 0.00
Current ratio — 1.54 4.79
Net debt to EBITDA — 1.84 1.01

Dividend

Metric CUVL VNDA Biotechnology median
Dividend yield 0.62% — 0.41%
Payout ratio — — —

Size

Metric CUVL VNDA Biotechnology median
Market cap 237.81m 235.22m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack